466 F.Supp.3d 382
S.D.N.Y.2020Background:
- Mueller Water Products sold AMI ("smart") water meters with 10‑year warranties and emphasized AMI as a growth, higher‑margin part of its Technologies segment.
- Plaintiffs allege widespread defects (radio "Version 3" podding/battery issues, moisture, register glitches) at customers including Missouri American Water, Chillicothe, San Diego, and Santee, resulting in returns and replacements.
- Mueller periodically accrued warranty reserves; it announced a discrete $9.8M warranty charge in April 2017 (Version 3 radios) and a $14.1M charge in August 2018 (broader reserve increase based on a new analysis). Stock fell after both disclosures.
- Plaintiffs (shareholders) sued under §10(b)/Rule 10b‑5, relying on confidential witnesses, press articles, and the timing/size of warranty charges to allege falsity and scienter; defendants moved to dismiss under Rules 12(b)(6) and 9(b).
- The district court dismissed the Second Amended Complaint with prejudice, holding plaintiffs failed to plead actionable misstatements/omissions or a strong inference of scienter and that many challenged statements were nonactionable opinions or adequately hedged disclosures.
Issues:
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Mueller materially misstated/omitted in accounting for warranty reserves | Mueller understated warranty reserves each quarter and therefore misstated expenses/liabilities | Warranty reserve estimates are subjective GAAP estimates/opinions; company adjusted reserves as new info arrived | Dismissed: plaintiffs failed to plead falsity—no specific facts showing defendants lacked honest belief or knew reserves were inadequate |
| Whether generic risk disclosures were misleading because risks had already materialized | Risk warnings hid the fact that significant defects and warranty costs were already occurring | Risk language was generic hedging and properly disclosed that new products may have defects and that costs were uncertain | Dismissed: generic cautionary language would not have misled a reasonable investor; not a "Grand Canyon" concealed by a warning |
| Whether statements about the April 2017 $9.8M charge, May 2018 call, and SOX certifications were false | Statements claiming recent awareness, error‑proofing, adequacy of charge, and effective controls were false; SOX certs therefore false | Those statements were sincerely held opinions/forward‑looking or accurate at the time; SOX certs not a standalone basis absent primary violation | Dismissed: challenged statements were nonactionable opinions/forward‑looking or adequately hedged; SOX certifications fail absent underlying falsity |
| Whether plaintiffs pleaded scienter (motive/opportunity or recklessness) | Insider sales and confidential witness reports show knowledge and motive to conceal defects | Insider sales tied to option expirations/retirements and CW allegations are vague, rumor, or not tied to accounting personnel | Dismissed: scienter not plausibly alleged—sales not suspicious; CWs too vague to show defendants knew reserves were false; no strong inference of conscious misbehavior |
Key Cases Cited
- Rombach v. Chang, 355 F.3d 164 (2d Cir. 2004) (Rule 9(b) particularity and securities pleading standards)
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (plausibility pleading standard)
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (legal conclusions vs. factual allegations)
- Omnicare, Inc. v. Laborers Dist. Council Constr. Indus. Pension Fund, 575 U.S. 175 (2015) (when opinions are actionable and omissions that make opinions misleading)
- Fait v. Regions Fin. Corp., 655 F.3d 105 (2d Cir. 2011) (accounting estimates as opinions)
- Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011) (materiality and omission doctrines)
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007) (strong inference of scienter standard)
- Novak v. Kasaks, 216 F.3d 300 (2d Cir. 2000) (pleading scienter and knowledge of contrary facts)
- Halliburton Co. v. Erica P. John Fund, Inc., 573 U.S. 258 (2014) (elements of securities fraud and reliance connection)
- Dura Pharm., Inc. v. Broudo, 544 U.S. 336 (2005) (loss causation and fraud‑by‑hindsight caution)